Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Genomic Biomarkers Market Expected to Grow Between 2025 And 2029?
The market size for genomic biomarkers has witnessed a significant expansion in the past few years. Expected to swell from $7.42 billion in 2024 to $8.72 billion in 2025, it promises a Compound Annual Growth Rate (CAGR) of 17.4%. This increase throughout the historic period can be credited to the growing focus on different genetic testing procedures, a surge in chronic disease cases, rising traction on precision medicine initiatives, increased preferences for companion diagnostics, and escalating patient cases with neurological disorders.
What Growth Rate Is Anticipated for the Genomic Biomarkers Market in the Coming Years?
The future years foresee a rapid expansion in the market size of genomic biomarkers, which is projected to escalate to $16.51 billion by 2029, with a compound annual growth rate (CAGR) of 17.3%. This progression during the forecasted period can be linked to factors such as the rising prevalence of ovarian and gastric cancer, heightened consciousness and endorsement of genetic testing, growing utilization of genomic biomarkers for cancer diagnosis and therapy, increasing cancer patient count, and the widening embrace of companion diagnostics. Key trends predicted for the upcoming period encompass next-generation sequencing (NGS), amalgamation with other omics, advancements in genomic technology, product innovation, and progression in healthcare services.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp
Who Are the Leading Companies in the Genomic Biomarkers Market?
Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4
What Are the Key Drivers of the Genomic Biomarkers Market?
The escalating need for personalized medicine, an approach that adjusts healthcare decisions and treatments to the unique genetic details of each patient, is predicted to stimulate the expansion of the genomic biomarkers market. The increase in demand can be attributed to factors such as a focus on patient-centered care, advancements in genetic sequencing and analysis, a patient-focused approach, and utilizing EHRs to store and analyze patient data. Genomic biomarkers are critical in personalized medicine as they allow healthcare providers to customize treatments based on a patient’s unique genetic profile. This method, known as precision medicine, seeks to boost treatment effectiveness and reduce side effects by acknowledging genetic differences. As an example, in 2022, the US-based Personalized Medicine Coalition stated that 12 new bespoke medications were approved, constituting approximately 34% of all freshly approved treatments and a 34% growth from previous years. Therefore, it follows that the rise in demand for personalized medicine is a key driver in the growth of the genomic biomarkers market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19485&type=smp
What Are the Key Market Segments in the Genomic Biomarkers Industry?
The genomic biomarkersmarket covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Other End User
Subsegments:
1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility
2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers
What Are the Latest Trends in the Genomic Biomarkers Market?
Key businesses in the genomic biomarkers market are concentrating on the creation of innovative items like lung reagents. These efforts are geared towards enhancing the identification of specific genetic alterations in lung cancer, boosting the precision of diagnoses, and promoting personalized treatment plans utilizing cutting-edge genomic technologies. Lung reagents are specialized substances either chemical or biological in nature, used in diagnostic tests, research, or lung-related medical procedures, aiding in precision medicine by directing treatment options based on the specific genetic makeup of cancer. Biofidelity, a UK company known for its work on advanced genomic assays and precision diagnostics, exemplified this in December 2023 when they introduced the ASPYRE-Lung reagents. These reagents are designed to detect crucial genetic mutations and changes in lung cancer, proving to be indispensable for steering targeted treatments and personalised medicine strategies.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report
What Are the Key Regional Markets in the Genomic Biomarkers Industry?
North America was the largest region in the genomic biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19485
This Report Delivers Insight On:
1. How big is the genomic biomarkers market, and how is it changing globally?
2. Who are the major companies in the genomic biomarkers market, and how are they performing?
3. What are the key opportunities and risks in the genomic biomarkers market right now?
4. Which products or customer segments are growing the most in the genomic biomarkers market?
5. What factors are helping or slowing down the growth of the genomic biomarkers market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model